67/100 B · Critical risk
1 serious risk flag found TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.
  • 🔴 Insolvency / collective proceedings on file (1)

QUANTUM GENOMICS

Active 5599 7211 Active for 20 years

5599 · RC 487996647 · Active since 2005

B

Overview

QUANTUM GENOMICS is a 5599 registered , France, since 2005. The company operates in the 7211 sector. With reported revenue of 10K EUR in 2023. Its TraceComp score of 67 (B) indicates moderate risk with some areas to watch. With 20 years of operations, the company has an established track record in its market.

Company Information

Registration Number
487996647
Legal Form
5599
Registered
2005-12-23

Financial Profile

Latest filed accounts: FY 2023 · most recent available in public filings

Revenue (2023) 10,060 EUR
Net Income -3,170,947 EUR
Total Assets 3,746,771 EUR
Altman Z -5.62 distress

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

5 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
MATHIEU CLAUDE ROBERT Bigois Autre Current
+ 4 more in the full report

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Insolvency & Collective Proceedings

1 insolvency / collective-proceedings notice on file — most recent published 2025-09-18. A material adverse finding for counterparty and credit risk.

Insolvency notice types, titles, publication dates and official Gazette sources.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Research Output

Active research organization. 62 publications · 3,339 citations · h-index 30 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (52%) · Biochemistry, Genetics and Molecular Biology (30%) · Neuroscience (18%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 7 patents · 7 active · 7 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Revenue down 98% year-on-year
  • Net loss reported in FY 2023
  • Altman Z-Score in the distress zone — elevated insolvency risk on the model

Data Sources & Freshness

Data sourced from: bulk register.